Wegovy vs. Zepbound

At a glance

How they work differently

Wegovy activates only the GLP-1 receptor. Zepbound activates both GLP-1 and GIP receptors — the "dual agonist" mechanism. In practice, tirzepatide seems to produce stronger appetite suppression and better metabolic effects at comparable tolerability, which shows up in trial weight-loss numbers.

Head-to-head trial: SURMOUNT-5

Published in 2024, SURMOUNT-5 was the first direct comparison of Zepbound and Wegovy in adults with obesity but without diabetes. Over 72 weeks, patients on maximum-tolerated Zepbound lost 20.2% of body weight, vs. 13.7% on Wegovy — a 47% relative advantage. The safety profile was similar in both arms.

Side effects

Both cause nausea, constipation, diarrhea, and fatigue, mostly concentrated in the first 1–2 weeks after a dose bump. Zepbound patients report slightly more intense GI symptoms during the escalation phase but comparable long-term tolerability. Both carry the boxed thyroid-tumor warning and both are contraindicated in pregnancy, MEN 2, and personal history of medullary thyroid carcinoma.

Cost and insurance

List prices are comparable, but Lilly's direct-to-patient program (LillyDirect) sells Zepbound vials for cash-pay users at $349–$499/month — the cheapest legitimate brand pricing on the market as of 2026. Wegovy's cash-pay pharmacy channel (NovoCare) sells single-dose vials at ~$499/month for eligible commercially insured but uncovered patients.

Insurance coverage is a coin flip in either direction: employer plans that cover one usually cover both. Medicare covers Wegovy only under the CV-risk indication and Zepbound only under the sleep-apnea indication — not for weight loss alone.

Switching between them

Switching Wegovy → Zepbound (or vice versa) requires restarting at the lowest dose (Zepbound 2.5 mg or Wegovy 0.25 mg) even if you were on the top dose of the other. Titrate up on a 4-week schedule under your clinician's supervision. Some patients switch because coverage changed; others because they plateaued or the side effects on one weren't tolerable.

Which should you ask for?

• Maximum weight loss: Zepbound has the better efficacy data in head-to-head trials.
• Heart disease + obesity: Wegovy is the only one with an FDA CV-outcome indication.
• Obstructive sleep apnea + obesity: Zepbound has the OSA indication.
• Cash-pay, brand-name only: LillyDirect Zepbound vials ($349–$499) currently undercut NovoCare.

Realistic expectations

Trial averages are what happens with a max-tolerated dose plus lifestyle counseling. Real-world results are lower — many patients don't titrate to the top dose because of cost, coverage caps, or side effects. A realistic band is 10–15% on Wegovy and 15–20% on Zepbound over a year, with high individual variability.

FAQ